Research programme: natural killer and T-cell based vaccines - Vaccinex

Drug Profile

Research programme: natural killer and T-cell based vaccines - Vaccinex

Alternative Names: VX-25; VX-45

Latest Information Update: 08 Oct 2015

Price : $50

At a glance

  • Originator Vaccinex
  • Class Vaccines
  • Mechanism of Action Natural killer cell stimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer; Infections; Inflammation

Most Recent Events

  • 09 Feb 2015 Preclinical trials in Cancer in USA (Parenteral)
  • 09 Feb 2015 Preclinical trials in Infections in USA (Parenteral)
  • 09 Feb 2015 Preclinical trials in Inflammation in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top